[1] 王泽华.重视和规范宫颈癌的新辅助化疗[J].华中医学杂志,2007,31(6):423-424.
[2] Pecorelli S.Revised FIGO staging for carcinoma of the vulva,cervix,and endomet rium[J].Int J Gynaecol Obstet,2009,105(2):103-104.
[3] Frei E.Clinical cancer research:an embattled species[J].Cancer,1982,50(10):1979-1992.
[4] 张晓兰.紫杉醇联合卡铂化疗并同步放疗治疗中晚期宫颈癌52例近期疗效观察[J].中国实用妇科与产科杂志,2008,24(3):228-229.
[5] Serur E,Mathews RP,Gates J,et al.Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix[J].Gynecol Oncol,1997,2(65):348-356.
[6] 刘永珠,胡庆兰,黄华仪.巨块型宫颈癌术前静脉化疗的临床观察[J].临床与实验医学杂志,2007,6(3):34-35.
[7] Park DC,Kim JH,Lew YO,et al.Phase Ⅱtrial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[J].Gvencol Oncol,2004,92(1):59.
[8] 刘萍,陈春林,曾北蓝,等.宫颈癌术前动脉化疗的组织病理学动态变化及临床结局[J].中国实用妇科与产科杂志,2006,22(2):109-111.
[9] 严冬梅.宫颈癌术前新辅助化疗47例疗效观察[J].中华实用诊断与治疗杂志,2010,26(2):192-194.